Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under 50.OnJanuary12,VikingTherapeutics,Inc.(NASDAQ:VKTX)announcedasignificantmilestoneinthedevelopmentofitsobesitydrugVK2735.VikingTherapeutics,Inc.(VKTX)Targets50. On January 12, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced a significant milestone in the development of its obesity drug VK2735. Viking Therapeutics, Inc. (VKTX) Targets 150B Obesity Drug Market amid VK2735 Topline Results Data published in the peer-reviewed journal Obesity show that the drug achieved a weight loss of 14.7% from baseline after 13 weeks of treatment, with no plateau observed. The clinical trial ...

Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline - Reportify